Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol
Tóm tắt
The anticancer drug, 6-mercaptopurine (6MP) is subjected to metabolic clearance through xanthine oxidase (XOD) mediated hydroxylation, producing 6-thiouric acid (6TUA), which is excreted in urine. This reduces the effective amount of drug available for therapeutic efficacy. Co-administration of allopurinol, a suicide inhibitor of XOD, which blocks the hydroxylation of 6MP inadvertently enhances the 6MP blood level, counters this reduction. However, allopurinol also blocks the hydroxylation of hypoxanthine, xanthine (released from dead cancer cells) leading to their accumulation in the body causing biochemical complications such as xanthine nephropathy. This necessitates the use of a preferential XOD inhibitor that selectively inhibits 6MP transformation, but leaves xanthine metabolism unaffected. Here, we have characterized two such unique inhibitors namely, 2-amino-6-hydroxy-8-mercaptopurine (AHMP) and 2-amino-6-purinethiol (APT) on the basis of IC50 values, residual activity in bi-substrate simulative reaction and the kinetic parameters like Km, Ki, kcat. The IC50 values of AHMP for xanthine and 6MP as substrate are 17.71 ± 0.29 μM and 0.54 ± 0.01 μM, respectively and the IC50 values of APT for xanthine and 6MP as substrates are 16.38 ± 0.21 μM and 2.57 ± 0.08 μM, respectively. The Ki values of XOD using AHMP as inhibitor with xanthine and 6MP as substrate are 5.78 ± 0.48 μM and 0.96 ± 0.01 μM, respectively. The K i values of XOD using APT as inhibitor with xanthine and 6MP as substrate are 6.61 ± 0.28 μM and 1.30 ± 0.09 μM. The corresponding Km values of XOD using xanthine and 6MP as substrate are 2.65 ± 0.02 μM and 6.01 ± 0.03 μM, respectively. The results suggest that the efficiency of substrate binding to XOD and its subsequent catalytic hydroxylation is much superior for xanthine in comparison to 6MP. In addition, the efficiency of the inhibitor binding to XOD is much more superior when 6MP is the substrate instead of xanthine. We further undertook the toxicological evaluation of these inhibitors in a single dose acute toxicity study in mice and our preliminary experimental results suggested that the inhibitors were equally non-toxic in the tested doses. We conclude that administration of either APT or AHMP along with the major anti-leukemic drug 6MP might serve as a good combination cancer chemotherapy regimen.
Tài liệu tham khảo
Pinkel D: Intravenous mercaptopurine: life begins at 40. J Clin Oncol. 1993, 11: 1826-1831.
Burchenal JH, Murphy ML, Ellison RR, Sykes MP, Tan TC, Leone LA, Karnofsky DA, Craver LF, Dargeon HW, Rhoads CP: Clinical evaluationof a new antimetabolite, 6-mercaptopurine in the treatment of leukemia and allied diseases. Blood. 1953, 8: 965-999.
Weigel G, Griesmacher A, DeAbreu RA, Wolner E, Mueller MM: Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Thromb Res. 1999, 94: 87-94. 10.1016/S0049-3848(98)00199-6.
Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992, 43: 329-339. 10.1007/BF02220605.
Elion GB: Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc. 1967, 26: 898-904.
Elion GB, Callahan S, Nathan H, Bieber S, Rundles RW, Hitchings GH: Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol. 1963, 12: 85-93. 10.1016/0006-2952(63)90012-1.
Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S: Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J Med Chem. 2005, 48: 392-402. 10.1021/jm049494r.
Anderson RF, Patel KB, Reghebi K, Hill SA: Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues. Br J Cancer. 1989, 60: 193-197.
Giler S, Sperling O, Brosh S, Urca I, De Vries A: Proceedings: Serum xanthine oxidase in hepatocellular damage. Isr J Med Sci. 1975, 11: 1225-
Kokoglu E, Belce A, Ozyurt E, Tepeler Z: Xanthine oxidase levels in human brain tumors. Cancer Lett. 1990, 50: 179-181. 10.1016/0304-3835(90)90262-V.
Vogler WR, Bain JA, Huguley CM, Palmer HG, Lowrey ME: Metabolic and therapeutic effects of allopurinol in patients with leukemia and gout. Am J Med. 1966, 40: 548-559. 10.1016/0002-9343(66)90118-5.
Elion GB, Callahan S, Rundles RW, Hitchings GH: Relationship between Metabolic Fates and Antitumor Activities of Thiopurines. Cancer Res. 1963, 23: 1207-1217.
Emmerson BT: The management of gout. N Engl J Med. 1996, 334: 445-451. 10.1056/NEJM199602153340707.
Rodnan GP: Treatment of the gout and other forms of crystal-induced arthritis. Bull Rheum Dis. 1982, 32: 43-53.
Massey V, Komai H, Palmer G, Elion GB: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970, 245: 2837-2844.
Vorbach C, Scriven A, Capecchi MR: The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev. 2002, 16: 3223-3235. 10.1101/gad.1032702.
Hille R, Nishino T: Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. Faseb J. 1995, 9: 995-1003.
Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF: Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci USA. 2000, 97: 10723-10728. 10.1073/pnas.97.20.10723.
Kaplan SR, Calabresi P: Drug therapy: immunosuppressive agents. N Engl J Med. 1973, 289: 1234-1236.
Venkat Raman G, Sharman VL, Lee HA: Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990, 228: 69-71.
Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG: Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983, 34: 810-817.
Jezewska MM: Effect of allopurinol (4-hydroxyprazolo(3,4-d)pyrimidine) on xanthine accumulation by milk xanthine oxidase in vitro. Eur J Biochem. 1974, 46: 361-365. 10.1111/j.1432-1033.1974.tb03628.x.
Galbusera C, Orth P, Fedida D, Spector T: Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol. 2006, 71: 1747-1752. 10.1016/j.bcp.2006.02.008.
Morre DJ: Preferential inhibition of the plasma membrane NADH oxidase (NOX) activity by diphenyleneiodonium chloride with NADPH as donor. Antioxi Redox Signal. 2002, 4: 207-212. 10.1089/152308602753625960.
Schang LM, Hwang GJ, Dynlacht BD, Speicher DW, Bantly A, Schaffer PA, Shilatifard A, Ge H, Shiekhattar R: Human PC4 is a substrate-specific inhibitor of RNA polymerase II phosphorylation. J Biol Chem. 2000, 275: 6071-6074. 10.1074/jbc.275.9.6071.
Ishibuchi S, Morimoto H, Oe T, Ikebe T, Inoue H, Fukunari A, Kamezawa M, Yamada I, Naka Y: Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2001, 11: 879-882. 10.1016/S0960-894X(01)00093-2.
Borges F, Fernandes E, Roleira F: Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem. 2002, 9: 195-217.
Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003, 278: 1848-1855. 10.1074/jbc.M208307200.
Tamta H, Thilagavathi R, Chakraborti AK, Mukhopadhyay AK: 6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies. J Enzyme Inhib Med Chem. 2005, 20: 317-324. 10.1080/14756360500112326.
Tamta H, Kalra S, Mukhopadhyay AK: Biochemical characterization of some Pyrazolopyrimidine-based inhibitors of xanthine oxidase. Biochemistry (Mosc). 2005, 71: S49-S54.
Massey V, Komai H, Palmer G, Elion GB: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1974, 245: 2837-2844.
Okamoto K, Nishino T: Mechanism of Inhibition of Xanthine oxidase with a new tight binding inhibitor. J Biol Chem. 1995, 270: 7816-7821. 10.1074/jbc.270.14.7816.
Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, Kato N: Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic Acid]: A potent Xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004, 311: 519-528. 10.1124/jpet.104.070433.
Sau AK, Mondal MS: Mixed inhibition of the oxidoreductase activity of xanthine oxidase by Pd+2 Ion. J Chem Soc Chem Comm. 1994, 13: 1547-1548. 10.1039/c39940001547.
Hoorn DECV, Nijveldt RJ, Leeuwen PAMV, Hofman Z, Rabbet LM, Bont DBAde, Norren KV: Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids. Eur J Pharmacol. 2002, 451: 111-118. 10.1016/S0014-2999(02)02192-1.
Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF: Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Nat Acad Sci USA. 2000, 97: 10723-10728. 10.1073/pnas.97.20.10723.
Okamoto K, Masumoto K, Hille R, Eger BT, Pai EF, Nishino T: Thecrystal structure of xanthine oxidoreducatse during catalysis: Implicationsfor reaction mechanism and enzyme inhibition. Proc Nat Acad Sci USA. 2004, 101: 7931-7936. 10.1073/pnas.0400973101.
Tai LA, Hwang KC: Cooperative catalysis in the homodimer subunits of xanthine oxidase. Biochem. 2004, 43: 4869-4876. 10.1021/bi035467b.
Hawkes TR, George GN, Bray RC: The structure of theinhibitory complex of alloxanthine (1H-pyrazolo[3,4-d]pyrimidine-4,6-diol) with the molybdenum centre of xanthine oxidase from electron-paramagnetic-resonance spectroscopy. Biochem J. 1984, 218: 961-968.
Hille R, Massey V: Tight binding inhibitors of xanthine oxidase. Pharm Ther. 1981, 14: 249-263. 10.1016/0163-7258(81)90063-2.
Ichimori K, Fukahori M, Nakazawa H, Okamoto K, Nishino T: Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide: Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form. J Biol Chem. 1999, 274: 7763-7768. 10.1074/jbc.274.12.7763.
Fersht A, (ed): Enzyme Structure and Mechanism. 1984, Cambridge: W.H. Freeman & Company, 2
Fathallah-Shaykh S: Xanthinuria. WebMD. 2005, last updated August 2006, [http://www.emedicine.com/ped/byname/xanthinuria.htm]
Pea F: Pharmacology of drugs for hyperuricemia: Mechanisms, Kinetics and Interactions. Contrib Nephrol. 2005, 147: 35-46.
Pomales R, Bieber S, Friedman R, Hitchings GH: Augmentation of the incorporation of hypoxanthine into nucleic acids by the administration of an inhibitor of xanthine oxidase. Biochim Biophys Acta. 1963, 72: 119-120. 10.1016/0006-3002(63)90222-1.
Fox IH, Wyngaarden JB, Kelley WN: Depletion of erythrocyte phosphoribosylpyrophosphate in man. N Engl J Med. 1970, 283: 1177-1182.
McCollister RJ, Gilbert WR, Ashton DM, Wyngaarden JB: Pseudofeedback Inhibition of Purine Synthesis by 6-Mercaptopurine Ribonucleotide and Other Purine Analogues. J Biol Chem. 1964, 239: 1560-1563.
Chalmers RA, Parker R, Simmonds HA, Snedden W, Watts RW: The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase. Biochem J. 1969, 112: 527-532.
Hille R, Massey V: Tight binding inhibitors of xanthine oxidase. Pharmacol Ther. 1981, 14: 249-263. 10.1016/0163-7258(81)90063-2.
Krenitsky TA, Elion GB, Strelitz RA, Hitchings GH: Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization. J Biol Chem. 1967, 242: 2675-2682.
Tamta H, Kalra S, Anand GCS, Mukhopadhyay AK: Differential nature of substrate affinity, kinetics and electron transfer reaction displayed by xanthine and 6-thioxanthine as substrates of milk xanthine oxidase. J Biol Phys Chem. 2005, 5: 89-99.
Escribano J, Garcia-Canovas F, Garcia-Carmona F: A kinetic study of hypoxanthine oxidation by milk xanthine oxidase. Biochem J. 1988, 254: 829-833.
Fundamentals of Enzyme Kinetics. Edited by: Cornish-Bowden, A. 2004, London: Portland Press, 3
Segel IH, (ed): Biochemical Calculations: How to Solve Mathematical Problems in General Biochemistry. 1976, Wiley, 2
Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA: Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000, 18: 1758-1763.